CLNN
Clene Inc.
There isn't enough reported data to score CLNN yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CLNN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CLNN's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CLNN PE Valuation
CLNN has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CLNN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CLNN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CLNN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.66 | +$1.01 |
| Q2 2026 | -$3.56 | +$0.48 |
| Q1 2026 | -$3.26 | +$1.06 |
| Q4 2025 | -$2.66 | +$3.37 |
| Q3 2025 | -$3.67 | +$2.35 |
| Q2 2025 | -$4.04 | +$1.16 |
| Q1 2025 | -$4.32 | +$5.62 |
| Q4 2024 | -$6.03 | +$5.11 |
CLNN is still losing money, but far less than before: $2.66 per share over the past year, against $17.63 at its worst in early 2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CLNN on earnings quality, reporting a profit while its opponent remains loss making.
CLNN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $56K | +273% |
| Q2 2026 | $90K | +233% |
| Q1 2026 | $15K | -81% |
| Q4 2025 | $77K | -15% |
| Q3 2025 | $15K | -83% |
| Q2 2025 | $27K | -70% |
| Q1 2025 | $81K | +11% |
| Q4 2024 | $91K | -46% |
CLNN's revenue is recovering but still below its 2023 peak: $56,000 last quarter, up 273% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11334% | +26319 points |
| Q2 2026 | -5941% | +15777 points |
| Q1 2026 | -13740% | -8708 points |
| Q4 2025 | -9734% | -223 points |
| Q3 2025 | -37653% | -28671 points |
| Q2 2025 | -21719% | -13597 points |
| Q1 2025 | -5032% | +7615 points |
| Q4 2024 | -9511% | -3670 points |
CLNN's operating margin was −11334% last quarter, up 26319 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CLNN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CLNN on profitability, with a higher operating margin.
CLNN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.7M | -$665K |
| Q1 2026 | -$4.5M | +$483K |
| Q4 2025 | -$4.8M | +$39K |
| Q3 2025 | -$4M | -$979K |
| Q2 2025 | -$4.7M | +$1.6M |
| Q1 2025 | -$5M | +$2.1M |
| Q4 2024 | -$4.9M | +$2.3M |
| Q3 2024 | -$3M | +$3.8M |
CLNN has burned cash in almost every quarter: −$18M over the past year, against −$18M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CLNN on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLNN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +2.3M shares |
| 1 year | +43% | +4.4M shares |
| 3 years | +128% | +8.2M shares |
| 5 years | +319% | +11.2M shares |
| Available history | +323% | +11.2M shares |
CLNN has 15M diluted shares, up 43% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CLNN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CLNN Net Leverage
CLNN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CLNN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 36.9 | Neutral |
CLNN's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CLNN PE vs Healthcare Sector
| Metric | CLNN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CLNN has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CLNN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.88 | 3.1% above |
| 20 week MA | $4.47 | 11% below |
| 50 week MA | $5.23 | 24% below |
| 100 week MA | $5.19 | 23% below |
| 200 week MA | $8.40 | 52% below |
CLNN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CLNN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.2 | $229.0 | +9.5% |
| 2021 | $229.0 | $87.4 | -62% |
| 2022 | $87.4 | $20.2 | -77% |
| 2023 | $20.2 | $5.93 | -71% |
| 2024 | $5.93 | $4.99 | -16% |
| 2025 | $4.99 | $6.25 | +25% |
| 2026 YTD | $6.25 | $4.00 | -36% |
CLNN has finished lower in four of the last six years. It's down 36% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CLNN on returns for 2026, with the stronger performance.